Long-term effects of natalizumab on MRI activity and clinical outcomes in Japanese patients with relapsing-remitting multiple sclerosis.
Annual Relapse Rate
Japanese
Magnetic resonance imaging
Natalizumab
Relapsing-remitting multiple sclerosis
Journal
BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555
Informations de publication
Date de publication:
29 Aug 2023
29 Aug 2023
Historique:
received:
14
12
2022
accepted:
20
06
2023
medline:
31
8
2023
pubmed:
30
8
2023
entrez:
29
8
2023
Statut:
epublish
Résumé
Relapsing-remitting multiple sclerosis (RRMS) is the most common phenotype of multiple sclerosis (MS), and its active stage is characterized by active T2 lesions with or without gadolinium (Gd) enhancement on magnetic resonance imaging (MRI). Natalizumab is indicated as monotherapy in adults with active RRMS in Japan. The main objective of this study was to investigate the long-term effect of natalizumab on disease progression in Japanese patients with RRMS using MRI data. This retrospective, chart review study was conducted at a single center in Japan. The main study outcome was the yearly proportion of patients with active T2-weighted image lesions detected with or without Gd enhancement on brain MRI (incidence rate) after treatment initiation for up to 5 years. Additional endpoints included annual relapse rate (ARR) and expanded disability status scale (EDSS) score. This study included data from 85 patients with RRMS who had received natalizumab for ≥ 1 year; of these, 65 (76.5%) were female and the mean ± standard deviation (SD) age at baseline was 37.5 ± 10.0 years. The incidence rate of active T2 lesions was 52.9% (45/85) in the year prior to natalizumab treatment (Year - 1), which decreased to 2.4% and 1.6% in Year 0.5-1.5 and Year 1.5-2.5, respectively. No active T2 lesions were detected in Year 2.5-5.5 in patients who continued natalizumab treatment. EDSS score was stable, improved, and worsened in 61.8%, 26.3%, and 11.8% of patients, respectively. The median (range) EDSS score was 2.0 (0.0-7.0) at baseline (n = 85) and remained within a similar range (median score between 1.0 and 2.25 during Years 1-5). ARR decreased from 1.12 relapses per year at baseline to 0.12 relapses per year during Year 1 and remained below 0.15 relapses per year up to Year 5. The results of this first long-term study evaluating the effect of natalizumab on MRI activity and clinical outcomes in Japanese patients with RRMS suggest that natalizumab markedly reduced disease activity and maintained effectiveness over several years.
Sections du résumé
BACKGROUND
BACKGROUND
Relapsing-remitting multiple sclerosis (RRMS) is the most common phenotype of multiple sclerosis (MS), and its active stage is characterized by active T2 lesions with or without gadolinium (Gd) enhancement on magnetic resonance imaging (MRI). Natalizumab is indicated as monotherapy in adults with active RRMS in Japan. The main objective of this study was to investigate the long-term effect of natalizumab on disease progression in Japanese patients with RRMS using MRI data.
METHODS
METHODS
This retrospective, chart review study was conducted at a single center in Japan. The main study outcome was the yearly proportion of patients with active T2-weighted image lesions detected with or without Gd enhancement on brain MRI (incidence rate) after treatment initiation for up to 5 years. Additional endpoints included annual relapse rate (ARR) and expanded disability status scale (EDSS) score.
RESULTS
RESULTS
This study included data from 85 patients with RRMS who had received natalizumab for ≥ 1 year; of these, 65 (76.5%) were female and the mean ± standard deviation (SD) age at baseline was 37.5 ± 10.0 years. The incidence rate of active T2 lesions was 52.9% (45/85) in the year prior to natalizumab treatment (Year - 1), which decreased to 2.4% and 1.6% in Year 0.5-1.5 and Year 1.5-2.5, respectively. No active T2 lesions were detected in Year 2.5-5.5 in patients who continued natalizumab treatment. EDSS score was stable, improved, and worsened in 61.8%, 26.3%, and 11.8% of patients, respectively. The median (range) EDSS score was 2.0 (0.0-7.0) at baseline (n = 85) and remained within a similar range (median score between 1.0 and 2.25 during Years 1-5). ARR decreased from 1.12 relapses per year at baseline to 0.12 relapses per year during Year 1 and remained below 0.15 relapses per year up to Year 5.
CONCLUSION
CONCLUSIONS
The results of this first long-term study evaluating the effect of natalizumab on MRI activity and clinical outcomes in Japanese patients with RRMS suggest that natalizumab markedly reduced disease activity and maintained effectiveness over several years.
Identifiants
pubmed: 37644415
doi: 10.1186/s12883-023-03297-1
pii: 10.1186/s12883-023-03297-1
pmc: PMC10463665
doi:
Substances chimiques
Natalizumab
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
311Subventions
Organisme : Biogen Japan Ltd.
ID : N/A
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Neurology. 2014 Jul 1;83(1):78-86
pubmed: 24898925
Lancet Neurol. 2009 Mar;8(3):254-60
pubmed: 19201654
Neurol Ther. 2017 Jun;6(1):39-55
pubmed: 27921221
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
N Engl J Med. 2006 Mar 2;354(9):899-910
pubmed: 16510744
Ann Neurol. 2014 Dec;76(6):802-12
pubmed: 25273271
Ann Neurol. 2019 May;85(5):653-666
pubmed: 30851128
Cochrane Database Syst Rev. 2011 Oct 05;(10):CD007621
pubmed: 21975773
J Clin Virol. 2013 Jun;57(2):141-6
pubmed: 23465394
Adv Ther. 2021 Jul;38(7):3724-3742
pubmed: 34014549
Mult Scler Relat Disord. 2012 Oct;1(4):188-95
pubmed: 25877266
Neurology. 2018 Apr 24;90(17):777-788
pubmed: 29686116
Mult Scler Relat Disord. 2017 Jan;11:25-31
pubmed: 28104251
Lancet Neurol. 2017 Nov;16(11):925-933
pubmed: 28969984
N Engl J Med. 2003 Jan 2;348(1):15-23
pubmed: 12510038
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237
J Neurol Neurosurg Psychiatry. 2020 Jun;91(6):660-668
pubmed: 32234967
Eur J Neurol. 2018 Feb;25(2):334-339
pubmed: 29105222
Neurology. 2019 Oct 8;93(15):e1452-e1462
pubmed: 31515290
N Engl J Med. 2018 Jan 11;378(2):169-180
pubmed: 29320652
Neurol Ther. 2017 Dec;6(2):197-211
pubmed: 29119538